ArticleEnvironmental research2023
A prospective nested case-control study of serum concentrations of per- and polyfluoroalkyl substances and aggressive prostate cancer risk.
Article in Environmental research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- A metabolomic investigation of serum perfluorooctane sulfonate and perfluorooctanoate.Environment international · 2023Pooled it
- Associations of serum per- and polyfluoroalkyl substances (PFAS) mixture with the risk of chronic diseases: evidence from single‑ , multi-pollutant, and machine learning models.Archives of toxicology · 2026Article
- Serum per- and polyfluoroalkyl substances in relation to circulating thyroxine levels and thyroid cancer risk: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial cohort.Environment international · 2026Article
- Circulating per- and polyfluoroalkyl substances and risk of pancreatic cancer: A nested case-control study within the NYU Women's health study.Environmental pollution (Barking, Essex : 1987) · 2025Article
- Review
- Investigating the role of neighborhood socioeconomic status and germline genetics on prostate cancer risk.HGG advances · 2025Article
- Endocrine-disrupting chemicals as prostate carcinogens.Nature reviews. Urology · 2025Review
- Circulating per- and polyfluoroalkyl substances and liver cancer risk: a nested case-control analysis of individual participant data from 12 prospective cohorts.Environmental health perspectives · 2025Article
- Health Impacts of Per- and Polyfluoroalkyl Substances (PFASs): A Comprehensive Review.Life (Basel, Switzerland) · 2025Review
- Plasma perfluoroalkyl substances and breast cancer risk in Brazilian women: a case-control study.Environmental health : a global access science source · 2025Article
- Unveiling the Research Void: Exploring the Reproductive Effects of PFAS Compounds on Male Health.Advances in experimental medicine and biology · 2025Review
- Perfluoroalkyl and polyfluoroalkyl substances and Cancer risk: results from a dose-response Meta-analysis.Journal of environmental health science & engineering · 2024Article
- A case-cohort study of per- and polyfluoroalkyl substance concentrations and incident prostate cancer in the cancer prevention Study-II LifeLink cohort study.Environmental research · 2024Article
- Serum concentrations of per- and polyfluorinated substances and risk of B-cell non-Hodgkin lymphoma.Environment international · 2024Article
- An exploratory analysis of the impact of area-level exposome on geographic disparities in aggressive prostate cancer.Scientific reports · 2024Article
- Large-Scale Screening of Per- and Polyfluoroalkyl Substance Binding Interactions and Their Mixtures with Nuclear Receptors.International journal of molecular sciences · 2024Article
- Case-Cohort Study of the Association between PFAS and Selected Cancers among Participants in the American Cancer Society's Cancer Prevention Study II LifeLink Cohort.Environmental health perspectives · 2023Article
- Serum concentrations of per- and polyfluoroalkyl substances and risk of renal cell carcinoma in the Multiethnic Cohort Study.Environment international · 2023Article
- Nested Case-Control Studies Investigating Serum Perfluorooctanoate and Perfluorooctane Sulfonate Levels and Pancreatic Ductal Adenocarcinoma in Two Cohorts.Environmental health perspectives · 2023Article
- The adverse role of endocrine disrupting chemicals in the reproductive system.Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Per- and polyfluoroalkyl substances (PFAS) are environmentally persistent organic pollutants detectable in the serum of most U.S. adults. Some studies of highly-exposed individuals have suggested an association between PFAS and prostate cancer, but evidence from population-based studies is limited. We investigated the association between pre-diagnostic serum PFAS concentrations and aggressive prostate cancer risk in a large prospective study. We measured pre-diagnostic serum concentrations of eight PFAS, including perfluorooctanoate (PFOA), for 750 aggressive prostate cancer cases and 750 individually matched controls within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. We assessed the reproducibility of PFAS concentrations in serial samples collected up to six years apart among 60 controls using intraclass correlation coefficients (ICCs). Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association with prostate cancer, adjusting for other PFAS and potential confounders. Concentrations of most PFAS were consistent (ICC>0.7) across the serial samples over time. We observed an inverse association between PFOA and aggressive prostate cancer (OR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.